Related Experiment Video

Updated: Sep 14, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

The Diagnostic Significance of Circulating Eicosanoid in Patients with Hypertrophic Cardiomyopathy

Yue Zhang1, Xinyu Liu1, Zhongze Zhang1

  • 1Tianjin Key Laboratory of Metabolic Diseases, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Center for Cardiovascular Diseases, Research Center of Basic Medical Sciences, Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China.

Journal of Cardiovascular Translational Research
|July 21, 2025
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) patients show lower levels of key eicosanoids, essential molecules involved in cardiovascular health. Specific eicosanoids like 12-HETE and EPA can help diagnose this hereditary heart disease.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Metabolomics

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent hereditary cardiovascular disease.
  • Eicosanoids are significant in cardiovascular diseases and function as biomarkers.

Purpose of the Study:

  • To profile plasma eicosanoids in HCM patients and healthy individuals.
  • To identify eicosanoids as potential biomarkers for HCM diagnosis.
  • To explore the relationship between eicosanoids and clinical markers in HCM.

Main Methods:

  • Plasma eicosanoids were profiled using liquid chromatography-mass spectrometry (LC-MS).
  • A cohort of 73 HCM patients and 78 healthy individuals was analyzed.
  • Metabolic network analysis and correlation studies were performed.

Main Results:

  • HCM patients exhibited downregulation of various eicosanoids, including arachidonic acid (AA), 5,6-DHET, 12-HETE, lipoxin A4 (LXA4), and eicosapentaenoic acid (EPA).
  • A predictive model using 12-HETE and EPA showed significant diagnostic value for HCM.
  • Eicosanoids like 17,18-EEQ, LXA4, and 13-oxo-ODE negatively correlated with hs-CRP and NT-proBNP levels in patients.

Conclusions:

  • Alterations in eicosanoid metabolism are implicated in the pathophysiology of HCM.
  • Specific eicosanoids, such as 12-HETE and EPA, hold potential as diagnostic biomarkers for HCM.
  • Eicosanoid profiles may offer insights into disease severity and associated inflammatory markers in HCM.

Keywords:
BiomarkersEicosanoidsHypertrophic cardiomyopathyMetabolomics

More Related Videos

Ultrasonic Assessment of Myocardial Microstructure10:53

Ultrasonic Assessment of Myocardial Microstructure

Published on: January 14, 2014

5.6K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
65
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
51
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
217
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23